

Docket No. 3479-4000US1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Yukio Kawamura et al.

Group Art Unit:

1642

Serial No.:

09/911,969

Examiner:

To be assigned

Filed:

July 24, 2001

For:

ANTITUMOR PROTEIN AND GENE ENCODING SAME

#### EXPRESS MAIL CERTIFICATE

Express Mail Label No.:

EL 853248895 US

Date of Deposit:

**November 9, 2001** 

I hereby certify that the following attached paper(s) and/or fee

- 1. Transmittal of Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed in Parent Application 09,023,731, now US Patent No. 6,291,648 B1
- 2. Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed in Parent Application 09,023,731, now US Patent No. 6,291,648 B1.
- 3. Copy of Notice to Comply.
- 4. Return receipt postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Arline E. Walz

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile



### <u>IN 78HE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Applicant(s): Kawamura et al.

Group Art Unit:

1642

Serial No.:

09/911,969

Examiner:

To be assigned

Filed:

July 24, 2001

For:

ANTITUMOR PROTEIN AND GENE ENCODING SAME

# TRANSMITTAL OF LETTER REQUESTING TRANSFER OF THE COMPUTER READABLE FORM OF THE SEQUENCE LISTING FILED IN PARENT APPLICATION 09,023,731, NOW US PATENT NO. 6,291,648 B1

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith is/are the following items for the above-identified application:

By:

$\bowtie$	Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed
	in Parent Application 09,023,731, now US Patent No. 6,291,648 B1

Copy of Notice to Comply

Return receipt Postcard

	Please charge the required fee of \$	to Deposit Account No. <u>13-4500</u> , Order No.
--	--------------------------------------	---

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3479-4000US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2001

Kenneth H. Sonnenfeld

Registration No. 33,285

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone

(212) 751-6849 Facsimile



**PATENT** 

Docket No.: 3479-4000US1

JITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Kawamura et al.

Group Unit: 1642

Serial No.

09/911,969

Examiner: To Be Assigned

Filed

July 24, 2001

For

ANTITUMOR PROTEIN AND GENE ENCODING SAME

Commissioner for Patents Washington, D.C. 20231 Attn: Box Application

# LETTER REQUESTING TRANSFER OF THE COMPUTER READABLE FORM OF THE SEQUENCE LISTING FILED IN PARENT APPLICATION 09,023,731, NOW US PATENT NO. 6,291,648 B1

The paper copy of the Sequence Listing in this application, 09/922,969, is identical to the computer readable copy of the Sequence Listing filed in application 09,023,731, now US Patent No. 6,291,648 B1, filed February 13, 1998. In accordance with 37 CFR 1.82(e), please use the only computer-readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included in the originallyfiled specification of the instant application.

**PATENT** 

Docket No.: 3479-4000US1

#### **AUTHORIZATION**

The Commissioner is hereby authorized to charge any additional fees which may be required for timely consideration of this Amendment under 37 C.F.R. §§1.16 -§1.20 or credit any overpayment to Deposit Account No. <u>13-4500</u>,Order No. <u>3479-4000US1</u>. **A** 

DUPLICATE COPY OF THIS PAGE IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2000

Kenneth H. Sonnenfeld

Registration No.: 33,285

#### Mailing Address:

MORGAN & FINNEGAN, L.L.P 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Telecopier

JAN 0 8 2002

TES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900 ISSIGNER FOR PATENTS

UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/911.969

07/24/2001

Yukio Kawamura

3479-4000US1

**CONFIRMATION NO. 4744** 

**FORMALITIES LETTER** 

\*OC000000006554118\*

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053

Date Mailed: 09/14/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

•	•			
■ For Rules Interpretation, call (703) 308-4216	380	2001		
■ To Purchase Patentin Software, call (703) 306-2600	AH	SEP	E in	
■ For Patentin Software Program Help, call (703) 306-4119 or e-mail	at.	<del>-</del> 0	<u></u>	
patin21help@uspto.gov or patin3help@uspto.gov	71	2	A12	
		Û		
CASE 3479 - 4000 USI SAL	NEG	U	130 134	
CASE ATTY OFF	₽	Æ		•
DUE DATE MARMAN 14 2001	<u>به</u>		•	
DUE DATE <u>MOUNDER</u> 14, 2001  A copy of this notice MUST be returned with the reply.	<u> </u>	<del></del>		
STATUTORY DATE April 14, 2002	70	•		

Ho

Customer Service Center

Initial Patent Examination Division (703) 368-1202

PART 1 - ATTORNEY/APPLICANT COPY